FDA reaches agreement with medical device lobby for user fees

NewsGuard 100/100 Score

The Advanced Medical Technology Association and FDA have reached an agreement in principle regarding reauthorization of the Medical Device User Fee and Modernization Act, according to AdvaMed President Steven Ubl, CQ HealthBeat reports.

Reauthorization of the user fee act is expected later this year.

Ubl on Tuesday said the agreement would make user fee increases more consistent and reduce agency review times.

Ubl declined to provide additional details. An FDA spokesperson confirmed that the agency reached an agreement with AdvaMed.

Ubl also discussed AdvaMed's policy agenda for the year, which includes working for passage of legislation that would establish Medicare reimbursements for doctors who use "remote monitoring technologies" to track chronic conditions.

Ubl said his group supports legislation that would alter how Medicare pays for new clinical lab tests that target therapies to individual patients.

Ubl added that AdvaMed is concerned about "the breadth and depth of reductions being discussed" for Medicare reimbursements (Carey, CQ HealthBeat, 2/27).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Biden is right about $35 insulin cap but exaggerates prior costs for Medicare enrollees